Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks

• Main Authors: Teng Luo (Author), Fei-Xiang Zhang (Author), Ke Zhao (Author), Hui-Ying Gao (Author), Shou-Guo Zhang (Author), Lin Wang (Author), Gui-Fang Dou (Author), Ting Liu (Author), Miao Yu (Author), Yi-Qun Zhan (Author), Hui Chen (Author), Xiao-Ming Yang (Author), Chang-Yan Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The compound [3-(1H-benzimidazol-2-methylene)-5-(2-methylphenylaminosulfo)-2-indolone], known as Indo5, is a novel selective inhibitor of c-Met and Trks, and it is a promising anticancer candidate against hepatocellular carcinoma (HCC). Assessing the pharmacokinetic properties, tissue distribution,...